| Title: |
Alemtuzumab treatment in Denmark:A national study based on the Danish Multiple Sclerosis Registry |
| Authors: |
Theodorsdottir, Asta; Debrabant, Birgit; Magyari, Melinda; Kant, Matthias; Rasmussen, Peter V.; Malmberg, Carl Fredrik; Norberg, Iver A.; Hansen, Victoria; Bech, Danny; Schmidt, Mathias F.; Schreiber, Karen; Frederiksen, Jette L.; Sellebjerg, Finn; Illes, Zsolt |
| Source: |
Theodorsdottir, A, Debrabant, B, Magyari, M, Kant, M, Rasmussen, P V, Malmberg, C F, Norberg, I A, Hansen, V, Bech, D, Schmidt, M F, Schreiber, K, Frederiksen, J L, Sellebjerg, F & Illes, Z 2021, 'Alemtuzumab treatment in Denmark : A national study based on the Danish Multiple Sclerosis Registry', Multiple Sclerosis Journal, vol. 27, no. 14, pp. 2254-2266. https://doi.org/10.1177/13524585211003291 |
| Publication Year: |
2021 |
| Collection: |
Aarhus University: Research |
| Subject Terms: |
adverse events; Alemtuzumab; CARE-MS; multiple sclerosis; observational study; real-world efficacy; registry |
| Description: |
Objective: To investigate clinical outcomes in a real-world setting in the complete population-based cohort of alemtuzumab-treated MS patients in Denmark. Methods: Data were retrieved from The Danish Multiple Sclerosis Registry between 2009 and 2019. Demographic and disease-specific patient parameters related to treatment history, efficacy, and safety outcomes were assessed at baseline and during follow-up visits. Results: A total of 209 patients (78% female) started treatment with alemtuzumab during the study period with 3.1 ± 1.4 years follow-up. After 2 years, 75% of patients were relapse-free compared to 48% the year before alemtuzumab (p < 0.001). The annual number of relapses was reduced by 69% in year 4 compared with the year prior alemtuzumab. More active disease before alemtuzumab increased the annual hazard rate for relapse (HR: 2.88, p < 0.001). The Expanded Disability Status Scale (EDSS) score remained stable or improved in 81% of patients after 2 years. The need for an additional treatment course was associated with higher number of relapses in the year before alemtuzumab (odds ratio (OR) = 1.95, p = 0.001). Conclusion: In a country with primarily escalation strategy, relapse rate reduction was maintained for 5 years, and EDSS stabilized/improved in majority of patients. Higher relapse rate 1 year before alemtuzumab increased the odds for additional courses. Novel serious AEs were not observed. |
| Document Type: |
article in journal/newspaper |
| Language: |
English |
| ISSN: |
1352-4585; 1477-0970 |
| Relation: |
info:eu-repo/semantics/altIdentifier/pmid/33779361; info:eu-repo/semantics/altIdentifier/pissn/1352-4585; info:eu-repo/semantics/altIdentifier/eissn/1477-0970 |
| DOI: |
10.1177/13524585211003291 |
| Availability: |
https://pure.au.dk/portal/en/publications/9979e0f0-0060-4710-87d0-876284c62004; https://doi.org/10.1177/13524585211003291; https://www.scopus.com/pages/publications/85103371082 |
| Rights: |
info:eu-repo/semantics/restrictedAccess |
| Accession Number: |
edsbas.95B7D03E |
| Database: |
BASE |